Safety and Efficacy of Pulmonary Rehabilitation for Long COVID Patients Experiencing Long-Lasting Symptoms.
Espérance MoineVirginie MolinierAdriana CastanyerAmandine CalvatGuillaume CosteAntonin VernetAudrey FaugéPerrine MagrinaJoan Lluis Aliaga-PareraNicolas OliverFrançois AlexandreNelly HeraudPublished in: International journal of environmental research and public health (2024)
Due to the high prevalence and persistence of long COVID, it is important to evaluate the safety and efficacy of pulmonary rehabilitation (PR) for patients who experience long-lasting symptoms more than six months after initial COVID-19 onset. Enrolled patients were admitted for a four-week in-patient-PR due to long COVID symptoms (n = 47). The safety of PR was confirmed by the absence of adverse events. Symptom-related outcomes were evaluated pre- and post-PR with significant score changes for: 6 min walking distance (61 [28 to 103] m), quality of life (mental Short Form-12: 10 [6 to 13], and physical: 9 [6 to 12]), Montreal Cognitive Assessment (1 [0 to 3]), fatigue (MFI-20: -19 [-28 to -8]), dyspnea (DYSPNEA-12: -7 [-9 to -2] and mMRC; -1 [-1 to 0]), Nijmegen questionnaire (-8 [-11 to -5]), anxiety and depression (HADS:-4 [-5 to -2] and -2 [-4 to -1], respectively) and posttraumatic stress disorder checklist scale (-8 [-12 to -4]). At the individual level, the percentage of symptomatic patients for each outcome decreased, with a high response rate, and the number of persistent symptoms per patient was reduced from six at PR initiation to three at the end of the program. Our results show that in-PR is safe and efficient at decreasing long-lasting symptoms experienced by long COVID patients at more than six months after initial disease onset.
Keyphrases
- sars cov
- coronavirus disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- sleep quality
- posttraumatic stress disorder
- chronic kidney disease
- pulmonary hypertension
- mental health
- prognostic factors
- peritoneal dialysis
- case report
- risk factors
- patient reported
- randomized controlled trial
- palliative care
- metabolic syndrome
- clinical trial
- quality improvement
- skeletal muscle
- mild cognitive impairment
- advanced cancer
- insulin resistance
- drug induced
- psychometric properties